
- Applied Clinical Trials-06-01-2015
- Volume 24
- Issue 6
Oncology Leads Personalized Medicine
Study finds that almost 75% of cancer drug candidates rely on biomarker data.
The opportunity to more precisely target and to personalize medical treatments based on biomarker data has attracted growing interest from biopharmaceutical companies. A recent study by the Tufts Center for the Study of Drug
Development (Tufts CSDD) finds that oncology dominates personalized medicine product development in part because cancer-related illnesses are extremely complex and they receive the highest level of R&D activity. Companies involved in developing personalized medicines report that across all phases, 73% of oncology drugs now rely on biomarker data. This compares with 42% of compounds in all indications.
- Tufts CSDD
Articles in this issue
over 10 years ago
FDA Seeks Resources to Support New Research Initiativesover 10 years ago
Safety Considerations for Follow-On Non-Biologic Complex Drugsover 10 years ago
Putting the EMA House in Orderover 10 years ago
Experts Call for Urgent Action on Antibiotics Researchover 10 years ago
Characterizing the Real Cost of Site Regulatory Complianceover 10 years ago
Using 505(b)(2) to Solve Shortfall from Generic Cliffover 10 years ago
Lifecycle Modeling and Simulation in Clinical Trialsover 10 years ago
The U.S. Biosimilar Pathway: Policy Precedes Scienceover 10 years ago
Managing Portfolios for Economic and Clinical Valueover 10 years ago
Applied Clinical Trials Digital Edition - June/July 2015Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.